LA
NVCR icon

Lee Ainslie’s NovoCure NVCR Stock Holding History

Lee Ainslie’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-592
Closed -$69K – 537
2021
Q3 		$69K Buy
+592
New +$89.5K ﹤0.01% 610
2020
Q4 		– Sell
-7,175
Closed -$799K – 745
2020
Q3 		$799K Sell
7,175
-12,846
-64% -$1.03M 0.01% 330
2020
Q2 		$1.19M Buy
+20,021
New +$1.32M 0.03% 284

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lee Ainslie's NVCR Position: Q4 2021 in Review

Lee Ainslie sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 592 shares — an estimated $69K sold.

Lee Ainslie first reported a position in NVCR in Q2 2020 and held it in 3 quarters. The position peaked at $1.19M in Q2 2020. 312 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

  • Lee Ainslie reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
  • Lee Ainslie sold 592 NovoCure shares in Q4 2021, an estimated $69K.
  • Lee Ainslie first reported a position in NovoCure in Q2 2020 and held it in 3 quarters.
  • Lee Ainslie's NovoCure position peaked at $1.19M in Q2 2020.
  • 312 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on Maverick Capital's 13F filing for Q4 2021, filed 14 Feb 2022.